论文部分内容阅读
对1987年6月至1989年6月联邦德国用含炔雌醇30μg+gestodene(一种19去甲睾酮衍生物)75μg的复合型口服避孕药(OC)的多中心试验结果进行报道。研究包括95906名育龄妇女(523477个周期),其中53.9%(2507峨4个周期)为首次使用OC(始用组),4G.z%(2d273s个周期)为曾用含炔雌醇+各种孕激素的OC后改用本药(改用组)。大部分妇女(81.6%)服药6个周期。共17688例’ (18.4%)停药者中10.8%为非医学原因,7.5%为不能接受的副反应。改用组中37。2%妇女对曾用过的OC有不能接受的副反应,但对现用OC80.2%认为
A multicenter trial of a combined oral contraceptive (OC) containing ethinyl estradiol 30 μg + gestodene (a 19-methyl-testosterone derivative) of 75 μg from June 1987 to June 1989 in the Federal Republic of Germany was reported. The study included 95,906 women of childbearing age (523,477 cycles), of which 53.9% (2507 cycles) were for the first time using OC (initial use) and 4G.z% (2 days 273 cycles) for ethinylestradiol The progesterone OC after the switch to the drug (switch to the group). Most women (81.6%) took 6 cycles. A total of 17,688 patients (18.4%) discontinued 10.8% for non-medical reasons, 7.5% unacceptable side effects. 37.2% of women switched to unacceptable adverse reactions to OC they had used, but considered 80.2% of current OCs